Table 1.
Baseline patients characteristics (1/2).
| Characteristic | All | Hyper-maturation | Intermediate maturation | Hypo-maturation | |
|---|---|---|---|---|---|
| Patients, no. | N | 87 | 21 (24.1) | 58 (66.7) | 8 (9.2) |
| Age at diagnosis | Mean (SD) | 46.9 (11.3) | 49.8 (9.9) | 46.0 (11.6) | 45.3 (12.3) |
| Sex ratio (M/F) | 1.2 | 2.5 | 0.9 | 1.7 | |
| FAB category | N (%) | ||||
| M0 | 1 (1.1) | 0 (0.0) | 1 (1.7) | 0 (0.0) | |
| M1 | 13 (14.9) | 3 (14.3) | 9 (15.5) | 1 (12.5) | |
| M1/M2 | 2 (2.3) | 1 (4.8) | 1 (1.7) | 0 (0.0) | |
| M2 | 19 (21.8) | 3 (14.3) | 14 (24.1) | 2 (25.0) | |
| M3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| M4 | 17 (19.5) | 2 (9.5) | 13 (22.4) | 2 (25.0) | |
| M4/M5 | 1 (1.1) | 0 (0.0) | 1 (1.7) | 0 (0.0) | |
| M5 | 22 (25.3) | 8 (38.1) | 11 (19.0) | 3 (37.5) | |
| M6 | 1 (1.1) | 0 (0.0) | 1 (1.7) | 0 (0.0) | |
| M7 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Unclassified | 1 (1.1) | 0 (0.0) | 1 (1.7) | 0 (0.0) | |
| NA | 10 (11.5) | 4 (19.0) | 6 (10.3) | 0 (0.0) | |
| Status at diagnosis | N (%) | ||||
| De novo | 86 (89.9) | 20 (95.2) | 58 (100.0) | 8 (100.0) | |
| t-AML | 1 (1.1) | 1 (4.8) | 0 (0.0) | 0 (0.0) | |
| White blood cell (109 cells/L) | Median (SD) | 24.7 (28.5) | 19.7 (37.7) | 29.2 (22.9) | 16.8 (41.5) |
| Cytogenetic prognosis | N (%) | ||||
| Favorable | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Intermediate | 87 (100.0) | 21 (100.0) | 58 (100.0) | 8 (100.0) | |
| Adverse | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Mutations in intermediate group | N (%) | ||||
| FLT3 ITDmut | 32 (36.8) | 7 (33.3) | 20 (34.5) | 5 (62.5) | |
| CEBPαmut/FLT3wt | 26 (29.9) | 6 (28.6) | 20 (34.5) | 0 (0.0) | |
| NPM1mut/FLT3wt | 5 (5.7) | 0 (0.0) | 5 (8.6) | 0 (0.0) | |
| ELN | N (%) | ||||
| Favorable | 30 (26.4) | 6 (28.6) | 24 (41.4) | 0 (0.0) | |
| Intermediate | 57 (65.5) | 15 (71.4) | 34 (58.6) | 8 (100) | |
| Adverse | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Blasts (blood) at diagnosis | Mean (SD) | 44.3 (33.1) | 50.5 (40.4) | 41.8 (30.5) | 46.7 (33.1) |
| Blasts (BM) at diagnosis | Mean (SD) | 62.2 (23.3) | 65.5 (23.9) | 59.0 (23.5) | 75.8 (14.8) |
| Response at day 15 | N (%) | 48 (55.2) | 11 (52.4) | 35 (60.3) | 2 (25.0) |
| No response at day 15 | 32 (36.8) | 7 (33.3) | 19 (32.8) | 6 (75.0) | |
| NA (not evaluable or induction death) | 7 (8.0) | 3 (14.3) | 4 (6.9) | 0 (0.0) | |
| Post-induction CR | N (%) | 73 (83.9) | 17 (81.0) | 50 (86.2) | 6 (75.0) |
| No post-induction CR | 14 (16.1) | 4 (19.0) | 8 (13.7) | 2 (25.0) | |
| Induction death | 5 (5.7) | 2 (9.5) | 2 (3.4) | 1 (12.5) | |
| No CR achieved | 9 (10.3) | 2 (9.5) | 6 (10.3) | 1 (12.5) | |
| Nb of induction for CR | N (%) | ||||
| 1 | 53 (60.9) | 12 (71.4) | 36 (62.1) | 2 (25.0) | |
| 2 | 15 (17.2) | 2 (9.5) | 10 (17.2) | 3 (37.5) | |
| 3 | 4 (4.6) | 0 (0.0) | 3 (5.2) | 1 (12.5) | |
| Allo-SCT | N (%) | 26 (29.9) | 6 (28.6) | 15 (25.9) | 5 (62.5) |
Allo-SCT, allogeneic stem cell transplantation; BM, bone marrow; CR, complete remission; FAB, French–American–British classification; M, male; F, female; ITD, internal tandem duplication; NA, not available; Nb, number; t-AML, therapy-related AML.